ArticleJournal of gastrointestinal oncology2019

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Manik Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.